MESO
Price
$13.65Alerts
Change
-$0.34 (-2.43%)
Updated
Nov 11 closing price
Capitalization
1.85B
13 days until earnings call
Intraday BUY SELL Signals
TRAW
Price
$0.25Alerts
Change
+$0.03 (+13.64%)
Updated
Nov 11 closing price
Capitalization
3.41M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

MESO vs TRAW

MESO vs TRAW Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MESO vs. TRAW commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MESO is a Hold and TRAW is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MESO with price predictions
Nov 11, 2026

Momentum Indicator for MESO turns positive, indicating new upward trend

MESO saw its Momentum Indicator move above the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 79 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MESO's RSI Indicator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for MESO just turned positive on October 28, 2026. Looking at past instances where MESO's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.

The 10-day moving average for MESO crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.

Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MESO advanced for three days, in 232 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

MESO moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

MESO broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MESO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. MESO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.260) is normal, around the industry mean (3.498). P/E Ratio (-32.140) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (29.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.504) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for TRAW with price predictions
Nov 11, 2026

TRAW sees MACD Histogram crosses below signal line

TRAW saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 35 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRAW as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The 10-day moving average for TRAW crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRAW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TRAW entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TRAW's RSI Indicator exited the oversold zone, 37 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRAW advanced for three days, in 177 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

TRAW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.017) is normal, around the industry mean (3.498). P/E Ratio (-0.121) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.824) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. TRAW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRAW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
MESO vs TRAW: Fundamental Ratings
MESO
TRAW
OUTLOOK RATING
1..100
951
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
87100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
6995
P/E GROWTH RATING
1..100
2798
SEASONALITY SCORE
1..100
5045

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRAW's Valuation (66) in the Biotechnology industry is in the same range as MESO (94). This means that TRAW’s stock grew similarly to MESO’s over the last 12 months.

MESO's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as TRAW (100). This means that MESO’s stock grew similarly to TRAW’s over the last 12 months.

MESO's SMR Rating (94) in the Biotechnology industry is in the same range as TRAW (100). This means that MESO’s stock grew similarly to TRAW’s over the last 12 months.

MESO's Price Growth Rating (69) in the Biotechnology industry is in the same range as TRAW (95). This means that MESO’s stock grew similarly to TRAW’s over the last 12 months.

MESO's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for TRAW (98). This means that MESO’s stock grew significantly faster than TRAW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MESOTRAW
RSI
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 6 days ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 6 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (MESO: $13.99 vs. TRAW: $0.25)
Brand notoriety: MESO and TRAW are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MESO: 43% vs. TRAW: 15%
Market capitalization -- MESO: $1.85B vs. TRAW: $3.41M
MESO [@Biotechnology] is valued at $1.85B. TRAW’s [@Biotechnology] market capitalization is $3.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MESO’s FA Score shows that 1 FA rating(s) are green while TRAW’s FA Score has 0 green FA rating(s).

  • MESO’s FA Score: 1 green, 4 red.
  • TRAW’s FA Score: 0 green, 5 red.
According to our system of comparison, MESO is a better buy in the long-term than TRAW.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MESO’s TA Score shows that 4 TA indicator(s) are bullish while TRAW’s TA Score has 4 bullish TA indicator(s).

  • MESO’s TA Score: 4 bullish, 5 bearish.
  • TRAW’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both MESO and TRAW are a bad buy in the short-term.

Price Growth

MESO (@Biotechnology) experienced а -5.28% price change this week, while TRAW (@Biotechnology) price change was -7.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

MESO is expected to report earnings on Nov 25, 2026.

TRAW is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

MESO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MESO has been loosely correlated with QTTB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MESO jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MESO
1D Price
Change %
MESO100%
-2.43%
QTTB - MESO
51%
Loosely correlated
-1.39%
SRPT - MESO
38%
Loosely correlated
+1.58%
MIST - MESO
33%
Poorly correlated
N/A
TNGX - MESO
33%
Poorly correlated
+5.88%
TRAW - MESO
31%
Poorly correlated
+11.11%
More

TRAW and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRAW has been loosely correlated with SLGL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if TRAW jumps, then SLGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRAW
1D Price
Change %
TRAW100%
+11.11%
SLGL - TRAW
47%
Loosely correlated
+3.09%
MESO - TRAW
34%
Loosely correlated
-2.43%
ELTX - TRAW
33%
Loosely correlated
+1.24%
TAOX - TRAW
32%
Poorly correlated
-1.55%
AXON - TRAW
32%
Poorly correlated
+4.26%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WTBA30.58-0.08
-0.26%
West Bancorporation
DKS149.58-0.42
-0.28%
Dick's Sporting Goods
FCPT23.39-0.14
-0.59%
Four Corners Property Trust
ICG1.46-0.03
-1.69%
Intchains Group Limited
VWAV1.04-0.23
-18.11%
Visionwave Holdings Inc